Cyclerion Q2 net loss $16.2M; cash $70M; pipeline advances; praliciguat licensed to Akebia for up to $585M milestones

Cyclerion Therapeutics, Inc.

2022-Q2 EPS reported -$0.85 revenue$3,062,000

Net loss of $16.2M in Q2 2021 vs $19.5M in Q2 2020; cash $70M as of June 30, 2021, up from $45M in March.
CY6463 Phase 2a trial initiated in Alzheimer's with vascular pathology (ADv); Ph1b in CIAS start-up; MELAS data expected by year-end 2021.
Exclusive global license of praliciguat to Akebia Therapeutics; Cyclerion eligible for up to $585M milestones plus tiered royalties.
Closed $18M private placement with EcoR1, Slate Path, MFN, Invus, and others; net $12.5M from ATM offering in Q2.
Errol De Souza appointed to Board of Directors; expanded Beacon Biosignals partnership for biomarker identification.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.